Pharma gives a damn about 'bad reputation'
This article was originally published in Scrip
Lack of trust in the pharmaceutical industry will create a barrier against future collaborations with wider healthcare services and the effective implementation of innovative new drugs. This was a warning given by Jane Griffiths, Janssen company group chair EMEA, at the Eyeforpharma meeting in Barcelona.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.